Literature DB >> 15322935

Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona.

A Pérez1, P Sala, M Giménez, M Sierra, A Esteve, A Alonso, M Quesada, F Raspall, V Ausina, C Rodrigo.   

Abstract

In this study, 90 episodes of pneumococcal bacteremia that occurred over an 8-year period in two hospitals in Barcelona were analyzed retrospectively to determine the clinical and bacteriological characteristics of pneumococcal bacteremia, the risk factors for antibiotic resistance, the outcome, and the vaccine coverage. The mean age of the patients was 3.1 years and the male/female ratio was 1.7. The overall rates of penicillin-non-susceptible, cefotaxime-non-susceptible, and erythromycin-resistant isolates were 48.8, 24.4, and 25.5%, respectively. Antibiotic resistance was associated with children under the age of 2 years and with previous antibiotic treatment. The percentage of antibiotic resistance was higher in the nine episodes that occurred in patients with an underlying illness. The most prevalent serotypes identified were 1, 14, 6B, 18C, 5, and 19A. Serotypes 6A/B, 14, and 19A/F were isolated primarily from children under 2, whereas serotypes 1 and 5 were recovered more frequently from older children. Apparent relationships between serotypes 6A/B, 14, and 19A/F and occult bacteremia and between serotypes 1 and 5 and bacteremic pneumonia were confounded by the age variable. The proportion of bacteremic episodes preventable by all (7-valent, 9-valent, and 11-valent) of the conjugate pneumococcal vaccines was 60% in children under 2. In older children, the serotype coverage rate for the three formulations was 48, 87, and 87%, respectively. In summary, these data expand upon previous Spanish studies in which serotypes 1 and 5 were reported to be among the leading causes of severe systemic pneumococcal infections in children over 2, findings that should be taken into consideration when planning vaccine programmes. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322935     DOI: 10.1007/s10096-004-1197-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Streptococcus pneumoniae in children in Spain: 1990-1999.

Authors:  A Fenoll; I Jado; D Vicioso; S Berrón; J E Yuste; J Casal
Journal:  Acta Paediatr Suppl       Date:  2000-12

2.  Epidemiology of invasive Streptococcus pneumoniae infections in children in an area of Barcelona, Spain.

Authors:  V Pineda; D Fontanals; H Larramona; M Domingo; J Anton; F Segura
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

3.  Six year multicenter surveillance of invasive pneumococcal infections in children.

Authors:  Sheldon L Kaplan; Edward O Mason; EllenR Wald; Tina Q Tan; Gordon E Schutze; John S Bradley; Laurence B Givner; Kwang Sik Kim; Ram Yogev; William J Barson
Journal:  Pediatr Infect Dis J       Date:  2002-02       Impact factor: 2.129

4.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

5.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

Review 6.  [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine].

Authors:  J de Arístegui Fernández; J M Corretger Rauet; F García Martín; T Hernández-Sampelayo; F A Moraga Llop; C Rodrigo Gonzalo De Liria; J Ruiz Contreras
Journal:  An Esp Pediatr       Date:  2002-01

7.  Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998.

Authors:  E Miller; P Waight; A Efstratiou; M Brisson; A Johnson; R George
Journal:  Acta Paediatr Suppl       Date:  2000-12

8.  Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.

Authors:  R von Kries; A Siedler; H J Schmitt; R R Reinert
Journal:  Clin Infect Dis       Date:  2000-08-30       Impact factor: 9.079

9.  Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease.

Authors:  I R Friedland
Journal:  Pediatr Infect Dis J       Date:  1995-10       Impact factor: 2.129

Review 10.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more
  2 in total

1.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

Review 2.  Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?

Authors:  M A Fletcher; D S Laufer; E D G McIntosh; C Cimino; F J Malinoski
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.